Core Insights - The company achieved a milestone in 2025 by recording a net profit of $287 million, successfully turning around from a net loss of $645 million in the previous year, marking its first annual profit since inception [1] - Total revenue for the year reached $5.343 billion, representing a year-on-year growth of 40.2%, with product revenue netting $5.282 billion, up 39.8% [1] Revenue Breakdown - The core product, Baiyueze, generated $3.928 billion in global sales, a 48.6% increase, maintaining its leading position among BTK inhibitors [3] - Bai Ze An (Tislelizumab) contributed $737 million, growing by 18.8% [3] - Other products included Anjiao Wei (Denosumab) at $306 million, up 36.4%, and Beili Tuo (Bonetuzumab) at $104 million, up 40.2% [3] - Other income reached $60.97 million, a significant increase of 98.6%, primarily from royalties related to the collaboration with Amgen [4] Profitability and Cash Flow - Gross profit for 2025 was $4.67 billion, with a gross margin of 87.3%, up from 84.3% in 2024, driven by improved product mix and manufacturing efficiencies [5] - The company reported a net cash flow from operating activities of $1.128 billion, a turnaround from a net outflow of $141 million in the previous year [1] Cost Structure and Efficiency - Research and development expenses totaled $2.146 billion, a 9.9% increase, while sales and administrative expenses were $2.081 billion, up 13.7% [6] - The combined expenses accounted for 78.6% of product revenue, down from 90.2% the previous year, indicating improved operational leverage [6] Financial Health - As of the end of 2025, total assets were $8.189 billion, with shareholder equity at $4.361 billion and total liabilities at $3.827 billion [8] - The company secured approximately $768 million in term loans from financial institutions for refinancing short-term operational funding [8] Pipeline Progress - The company is advancing its pipeline with the approval of Sotokura (a new generation BCL2 inhibitor) expected in January 2026 for treating relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia [9] - The HERIZON-GEA-01 study for Bai He An (Zanidatamab) achieved positive endpoints, paving the way for a market application in HER2-positive gastric adenocarcinoma [9] - The company is uniquely positioned with potential best-in-class candidates across three key targets in chronic lymphocytic leukemia [9]

Core Viewpoint - The announcement by the company regarding the completion of patient enrollment in the Phase III clinical trial for mesutoclax (ICP-248) combined with BTK inhibitor ibrutinib for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) highlights a significant advancement in the development of innovative cancer therapies [1][4]. Group 1: Drug Development and Clinical Trials - Mesutoclax is a novel, oral, highly selective BCL2 inhibitor that targets the BCL2 protein, which is crucial in regulating apoptosis and is linked to various hematological malignancies [2][5]. - The combination of mesutoclax with ibrutinib aims to provide deeper remission for first-line CLL/SLL patients and prevent the emergence of drug-resistant mutations, offering hope for clinical cures [2][5]. - Data presented at the ASH annual meeting indicated that the 125 mg dose of mesutoclax achieved an overall response rate (ORR) of 100% in both treatment-naive and relapsed/refractory CLL/SLL patients, with a 65% rate of undetectable minimal residual disease (uMRD) after 36 weeks of treatment [2][5]. Group 2: Broader Clinical Applications - In addition to CLL/SLL, mesutoclax is also being investigated in clinical trials for mantle cell lymphoma (MCL) resistant to BTK inhibitors and has received breakthrough therapy designation in China [3][6]. - Clinical studies for mesutoclax are concurrently being conducted for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in multiple locations globally [3][6]. Group 3: Competitive Landscape - The global market for BCL2 inhibitors is limited in terms of products in Phase III trials, with most domestic competitors still in Phase I/II stages, positioning mesutoclax as a strategically significant asset for the company [4][7]. - The company aims to align its blood cancer therapies with international standards, enhancing its potential as a globally competitive innovative drug [4][7]. - The CEO emphasized the importance of mesutoclax in the company's hematology portfolio and the expected synergistic effects of combining BTK and BCL2 inhibitors to benefit patients [4][7].

Group 1 - The company announced the completion of patient enrollment for a Phase III clinical trial of its novel BCL2 inhibitor mesutoclax (ICP-248) in combination with BTK inhibitor ibrutinib for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [1][2][3] - Mesutoclax is a new oral, highly selective BCL2 inhibitor that restores apoptosis in tumor cells by selectively inhibiting BCL2 protein, which is crucial in the apoptosis pathway and is associated with various malignant hematological tumors [1][2][3] - The combination of mesutoclax and ibrutinib aims to provide deeper remission for first-line CLL/SLL patients and avoid the development of resistance mutations, presenting a significant potential treatment option [1][2][3] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting in December 2025, multiple studies on mesutoclax were presented, showing good efficacy and safety in both treatment-naive and relapsed/refractory CLL/SLL patients, with an overall response rate (ORR) of 100% in the 125 mg mesutoclax dose group [2][4] - The rate of undetectable minimal residual disease (uMRD) in patients treated with mesutoclax and ibrutinib after 36 weeks was reported to be 65% [2][4] - In addition to first-line CLL/SLL treatment, mesutoclax is advancing towards clinical trials for treating mantle cell lymphoma after BTK inhibitor resistance and has received China's first breakthrough therapy designation [2][4] Group 3 - CLL/SLL is one of the most common types of leukemia, characterized as an indolent malignancy of B lymphocytes, with approximately 191,000 new cases and 61,000 deaths globally each year, and an increasing incidence trend in China [5]

Group 1 - The core point of the news is that BeiGene's new BCL2 inhibitor, SOTUCLAR (百悦达®), has received conditional approval from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy including a BTK inhibitor, as well as for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic therapies including a BTK inhibitor [1][2] - SOTUCLAR is the first of its kind to be approved in China, allowing Chinese patients to benefit from this innovative therapy ahead of other markets [1] - The approval process in China took only 8 months from acceptance to approval, highlighting the urgent treatment needs of patients with blood cancers who have developed resistance [2] Group 2 - The approval of SOTUCLAR marks a significant milestone in BeiGene's hematology product pipeline and reinforces the company's leadership in the treatment of B-cell malignancies [2] - SOTUCLAR has also received breakthrough therapy designation and priority review qualification from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory MCL who have received BTK inhibitors, potentially making it the first BCL2 inhibitor approved for this indication in the U.S. [1]

Summary of BeOne Medicines Conference Call Company Overview - **Company**: BeOne Medicines (ONC/688235.SS) - **Industry**: Oncology - **Headquarters**: Switzerland - **Focus**: Discovering and developing innovative cancer treatments, with a portfolio in hematology and solid tumors, including products like Brukinsa and Tevimbra [7][10] Key Points from the Conference Call Approval and Market Entry - **Sonro Approval**: On January 5th, 2025, the China NMPA approved sonrotoclax (BCL2 inhibitor) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and mantle cell lymphoma (R/R MCL) [1] - **Approval Timeline**: The NDA review took only eight months, which is considered quick compared to the typical 12-18 months for new drug approvals, indicating a significant unmet need for BCL2 inhibitors in China [1] Market Dynamics - **Sales Ramp-Up**: There is a focus on tracking the sales ramp-up of venetoclax and lisaftoclax, as well as feedback from physicians and patients regarding the new BCL2 inhibitors [2] - **Differentiation Potential**: Sonrotoclax and lisaftoclax are expected to disrupt the market due to: 1. **Better Tolerability**: Both drugs showed lower rates of neutropenia and discontinuation compared to venetoclax, with sonrotoclax showing a lower rate than lisaftoclax [2] 2. **Quicker Dose Ramp-Up**: Lisaftoclax has a 4-6 days daily dose ramp-up scheme, while sonrotoclax and venetoclax follow a weekly ramp-up [2] Financial Projections - **Earnings Adjustments**: FY2025-2027 earnings estimates were adjusted, with EPS revised from US$3.78/US$6.26/US$6.64 to US$3.59/US$4.65/US$4.46 [6] - **Sales Estimates**: Near-term sales estimates for sonro were fine-tuned with increased SG&A investment, and R&D spending was increased due to multiple pipeline assets entering the proof of concept stage [6] - **Target Prices**: The 12-month target prices were updated to US$385.79 for ONC and Rmb345.86 for the A-share [6] Risks and Challenges - **Key Risks**: 1. Uncertainties in R&D and regulatory approvals, especially for the early-stage solid tumor franchise [7][10] 2. Competition from BTK and PD-1 inhibitors [7][10] 3. Development risks for clinical-stage assets [7][10] 4. Market access bottlenecks [7][10] Investment Rating - **Current Rating**: The company maintains a "Buy" rating, with shares trading at a modest discount due to broader macroeconomic factors and concerns around its product pipeline [7][10] Additional Insights - **Clinical Development Team**: BeOne Medicines has a growing internal clinical development team, which may provide cost savings and advantages in product launch times compared to peers [7] - **Market Position**: The company is well-positioned to grow and bring additional therapies to both the local Chinese market and the global pharmaceutical stage [7] This summary encapsulates the critical insights from the conference call regarding BeOne Medicines, its market strategies, financial outlook, and associated risks.

Core Insights - The company announced the presentation of three studies on its novel BCL2 inhibitor Mesutoclax (ICP-248) at the 67th American Society of Hematology (ASH) annual meeting [1] - Mesutoclax demonstrated excellent efficacy and safety in treating relapsed/refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML) [1] - The study on Mesutoclax for relapsed/refractory MCL was selected for oral presentation, while the studies for CLL/SLL and AML were selected for poster display [1]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a total revenue of approximately 27.595 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 44.2%. The net profit attributable to shareholders was approximately 1.139 billion yuan, with a non-recurring net profit of about 969 million yuan. For Q3 2025, the total revenue was approximately 10.077 billion yuan, up 41.1% year-on-year, with a net profit of about 689 million yuan and a non-recurring net profit of approximately 708 million yuan. The company has raised its full-year revenue guidance for 2025, expecting total revenue to be between 36.2 billion yuan and 38.1 billion yuan [1][2][3]. Revenue Growth Drivers - The adjustment in expected revenue growth is primarily attributed to the leading position of Baiyueze® in the U.S. market and its ongoing expansion in Europe and other key global markets. The adjustments in R&D, sales, and management expenses are mainly due to prudent investments that promote revenue and pipeline growth, achieving significant operational efficiency [2]. Market Performance - In Q3, Baiyueze® generated global revenue totaling 1 billion USD, a year-on-year increase of 50.8%. In the U.S., revenue reached 738.7 million USD, up 46.6% from the previous year, driven by robust demand across all indications and moderate gains from net pricing. In Europe, revenue totaled 163.2 million USD, a 67.8% increase year-on-year, benefiting from market share growth in major European markets. In China, revenue was 92.4 million USD, up 36.2% year-on-year, while sales in other countries reached 46.4 million USD, a 116.6% increase [3]. Pipeline and Future Prospects - The company announced that nearly 50 abstracts from its hematology research projects will be presented at this year's ASH annual meeting, including 6 oral presentations. Sotokura is gradually becoming a potential best-in-class BCL2 inhibitor, offering better efficacy, higher safety, and greater convenience compared to the first-generation BCL2 inhibitor, venetoclax. The U.S. FDA has granted breakthrough therapy designation to Sotokura for the treatment of relapsed/refractory mantle cell lymphoma [4]. Financial Forecast - The company forecasts revenues for 2025-2027 to be 37.7 billion yuan, 48 billion yuan, and 55.1 billion yuan respectively, with year-on-year growth rates of 38%, 28%, and 15%. The net profit attributable to shareholders is expected to be 736 million yuan, 4.692 billion yuan, and 7.982 billion yuan for the same years, reflecting significant growth [8][10].

Core Insights - BeiGene announced positive results from the Phase 1/2 clinical trial of its next-generation BCL2 inhibitor, Sotorasib, for treating adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitors and anti-CD20 therapies [1][2] - The trial demonstrated significant and durable responses, indicating the potential of Sotorasib to provide the first BCL2 inhibitor treatment option for MCL patients if approved [1][2] Company Developments - The clinical study (BGB-11417-201) enrolled 125 adult patients with MCL, assessing safety, tolerability, and efficacy of Sotorasib at doses of 160 mg and 320 mg [1] - The study achieved the primary endpoint of overall response rate (ORR) and showed positive results in secondary endpoints, including complete response rate (CRR), duration of response (DOR), and progression-free survival (PFS) [2] - BeiGene is submitting data to the FDA and other global regulatory agencies for potential approval of Sotorasib in MCL, with the drug already accepted for priority review by China's NMPA [2] Industry Context - The study's results mark a significant milestone in BeiGene's product portfolio for hematologic malignancies, which currently includes three major products aimed at addressing the evolving clinical needs of B-cell malignancy patients [2] - The ongoing Phase 3 confirmatory CELESTIAL-RRMCL study (BGB-11417-302) has already enrolled its first patient earlier this year, further supporting the development of Sotorasib [2]

Core Insights - BeiGene announced positive results from the Phase 1/2 clinical trial of its investigational BCL2 inhibitor, Sotorasib, for treating adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitors and anti-CD20 therapies [1][2] - The trial demonstrated significant and durable responses, indicating the potential of Sotorasib to provide the first BCL2 inhibitor treatment option for MCL patients if approved [1][2] Group 1: Clinical Trial Details - The BGB-11417-201 study is a global, multicenter, single-arm, open-label Phase 1/2 trial that enrolled 125 adult MCL patients previously treated with BTK inhibitors and anti-CD20 therapies [1] - In the first part of the study, 22 patients received daily doses of either 160 mg or 320 mg of Sotorasib to assess safety and tolerability, leading to the determination of the recommended dose for the second part [1] - The second part involved 103 patients receiving the recommended daily dose of 320 mg to evaluate the efficacy and safety of Sotorasib [1] Group 2: Efficacy and Safety Results - The study achieved the primary endpoint of overall response rate (ORR) as assessed by an independent review committee (IRC), indicating clinically meaningful responses in the patient population [2] - Secondary efficacy endpoints, including complete response rate (CRR), duration of response (DOR), and progression-free survival (PFS), also showed positive results [2] - The safety profile of Sotorasib was generally well-tolerated, with manageable toxicity, marking an important milestone in BeiGene's product portfolio for hematologic malignancies [2] Group 3: Regulatory and Market Implications - BeiGene is submitting data to the FDA and global regulatory agencies to seek potential approval for Sotorasib in the MCL indication [2] - The new drug application for Sotorasib for treating MCL and CLL/SLL patients has been accepted by the National Medical Products Administration (NMPA) in China and is under priority review [2] - A confirmatory Phase 3 study, CELESTIAL-RRMCL (BGB-11417-302), is ongoing, with the first patient enrolled earlier this year [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 自願性公告－業務發展最新情況 百濟神州宣佈索托克拉用於治療套細胞淋巴瘤(MCL)患者 的臨床研究取得積極結果 百濟神州有限公司（「百濟神州」或「本公司」）於2025年8月29日宣佈新一代且具有 同類最優潛力的在研BCL2抑制劑索托克拉用於治療既往接受過布魯頓氏酪氨酸激 酶(BTK)抑制劑和抗CD20治療的套細胞淋巴瘤(MCL)成人患者的1/2期臨床研究 (BGB-11417-201)取得積極結果，並計劃在即將召開的學術大會上公佈全部數據。 「對於MCL患者來說，疾病依然具有侵襲性，且治療選擇有限，療效也不盡如人 意。索托克拉的臨床研究結果表明其有潛力為MCL患者帶來顯著且持久的緩解。 若獲得批准，將為這部分患者提供首個BCL2抑制劑的治療選擇。」百濟神州全球 研發負責人汪來博士表示，「在過 ...